Morphogenesis, Inc.

Morphogenesis, Inc. is a biotechnology firm focused on developing innovative therapeutic solutions using proprietary antibody drug conjugates to enhance immune responses against cancers and immune-related conditions. Founded in 1995, Morphogenesis, Inc. is based in Tampa, US.

The company specializes in biotechnology with a focus on therapeutic solutions involving bi-specific immune modulating antibody drug conjugates. The current CEO is Patricia Lawman, who co-founded the company alongside Michael Lawman. In May 2018, Morphogenesis raised USD 16 mn in Series A funding, which was fully raised in this round. The investment was co-led by KP Biotech Group.

Morphogenesis develops IMMUNE FX (IFX), an innovative product line that includes bi-specific immune modulating antibody drug conjugates (ADCs). These products are designed to improve patient outcomes by selectively modulating immune pathways to combat cancers and other immune-related diseases. The primary users of these products are hospitals, oncology clinics, and healthcare providers, focusing on personalized medicine in North America, Europe, and select Asia-Pacific markets. Morphogenesis generates revenue through B2B collaborations, partnerships with healthcare institutions, and direct sales to specialized medical facilities.

Revenue streams include milestone payments and royalties from successful clinical advancements, along with direct product sales post-regulatory approval. The company aims to reflect the value of its innovative therapies in its pricing strategies. Following the most recent funding round in May 2018, Morphogenesis plans to utilize the USD 16 mn raised to support a Phase 1b human clinical trial at Tampa's Moffitt Cancer Center and to strengthen its executive management team. The company is focused on launching new products and expanding its market presence, although specific upcoming product release dates and geographic regions targeted for expansion have not been disclosed.